ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

	Company	Country	Ticker
	Alteogen Inc. Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.	South Korea	196170
	ALTERITY THERAPEUTICS LTD Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.	United States of America	ATHE
	Alto Neuroscience, Inc. Developing precision medicines for depression and schizophrenia using a brain biomarker platform.	United States of America	ANRO
	ALUMIS INC. Develops targeted oral therapies for immune-mediated diseases using precision immunology.	United States of America	ALMS
	Alvotech Develops and manufactures affordable biosimilar medicines for patients worldwide.	United States of America	ALVO
	Alvotech Holdings S.A Develops and manufactures affordable biosimilar medicines for global patient access.	Luxembourg	ALVO
	ALX ONCOLOGY HOLDINGS INC Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.	United States of America	ALXO
	Alzamend Neuro, Inc. Developing lithium & vaccine therapies for neurodegenerative & psychiatric disorders.	United States of America	ALZN
	Alzinova AB Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.	Sweden	ALZ
$AMARIN CORP PLC\UK Logo$	AMARIN CORP PLC\UK Develops prescription therapies like Vascepa® to reduce cardiovascular risk for patients.	United States of America	AMRN